Alexion Pharmaceuticals Stock News

Alexion (ALXN) delivered earnings and revenue surprises of 3.44% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Alexion Pharma earnings topped fourth-quarter views, but the biotech company gave light sales guidance for 2020. ALXN stock fell early Thursday.

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

For fourth-quarter 2019, earnings trends are improving as companies are coming up with their reports.

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Many of these industries have recently been valued at their lowest forward P/E in at least 22 years.

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

Alexion Pharmaceuticals (ALXN) closed at $112.79 in the latest trading session, marking a -0.99% move from the prior day.

Is (ALXN) Outperforming Other Medical Stocks This Year?

The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.

Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.

The key to winning in the stock market is pretty straightforward own a portfolio of winning stocks. The tricky part is identifying stocks that will win, as there’s no crystal ball that helps in this

These large-cap growth and value stocks could make you richer this year.